A study of GSK3β in Alzheimer’s disease found that acetylation of GSK3β at residue K15 (the equivalent of TgGSK K13) led to the over-activation of the kinase, which led to the promotion of tau hyperphosphorylation and an increase in disease phenotypes [39]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.